Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?

Fig. 1

a: Overall survival (OS) of 91 metastatic or locally advanced patients measured from the first dose of palliative chemotherapy. Median OS: 13.4 months (95% CI: 11.6–15.2). b: Overall survival of patients receiving first-line FOLFIRINOX and second-line nabPGem (median OS: 13.65 months (95% CI: 12.6–14.7) vs. nabPGem followed by FOLFIRINOX (median OS: 13.78 months (95% CI: 8.6–19), p = 0.94

Back to article page